AAV9 Vector Delivery of BAG3 for Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure and dilated cardiomyopathy, particularly idiopathic dilated cardiomyopathy, are inadequate as they fail to effectively address the underlying genetic and protein expression issues, leading to insufficient cardiac function and morbidity.
Innovation Solution
Development of compositions and methods to modulate the expression of Bcl-2 associated anthanogene-3 (BAG3) molecules using expression vectors and AAV9 vectors to overexpress BAG3 in cardiac tissues, thereby restoring normal ventricular function in patients with heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for heart failure are used, then treatment is provided, but they fail to effectively address the underlying genetic and protein expression issues, leading to insufficient cardiac function
Solution Approach 1:
The patent uses AAV9 vectors as intermediaries to deliver BAG3 gene therapy to cardiac tissues. The viral vector serves as a mediator between the therapeutic gene and the target cells, enabling effective gene transfer and expression modulation without direct genetic manipulation of the patient's cells
Solution Approach 2:
The patent changes the expression level parameter of BAG3 protein in cardiac tissues by introducing exogenous BAG3 genes via viral vectors. This parameter change addresses the underlying protein expression deficiency in heart failure patients, transforming the therapeutic approach from symptom management to root cause intervention
2Reliability
If BAG3 expression is modulated using expression vectors, then cardiac function is improved, but the complexity of the treatment increases
Solution Approach 1:
The AAV9 vector system serves multiple functions: it protects the therapeutic gene during delivery, enables specific targeting of cardiac tissues, and facilitates sustained gene expression. This multi-functionality consolidates what would otherwise require multiple separate treatment steps into a single therapeutic agent
Solution Approach 2:
The BAG3 gene therapy approach leverages the body's own cellular machinery to produce the therapeutic protein. Once the BAG3 gene is delivered via the viral vector, the patient's cardiac cells automatically transcribe and translate the gene into functional BAG3 protein, eliminating the need for continuous external administration
Data Source
AI summary
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.